Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
Public ClinicalTrials.gov record NCT05304351. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Observer-Blind, Phase 2 Study To Assess the Safety and Immunogenicity of CRV-101 Vaccine Head-To-Head With SHINGRIX® for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety and immunogenicity of amezosvatein (CRV-101), an investigational vaccine compared to Shingrix® for the prevention of herpes zoster in adults aged 50 years and older
Study identification
- NCT ID
- NCT05304351
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 1,516 participants
Conditions and interventions
Conditions
Interventions
- Amezosvatein Antigen High Dose Arm A Biological
- Amezosvatein Antigen Low Dose Arm B Biological
- Shingrix Biological
- Amezosvatein Adjuvant Dose Arm D Biological
- Amezosvatein Adjuvant Dose Arm F Biological
- Amezosvatein Adjuvant Dose Arm H Biological
- Amezosvatein Adjuvant Dose Arm J Biological
- Amezosvatein Adjuvant Dose Arm L Biological
Biological
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2, 2022 (Actual)
- Primary completion
- Jun 30, 2026 (Estimated)
- Completion
- Mar 6, 2032 (Estimated)
- Last update posted
- Sep 30, 2025
2022 – 2032
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Curevo Investigational Site | Tempe | Arizona | 85281 | — |
| Curevo Investigational Site | Coral Gables | Florida | 33134 | — |
| Curevo Investigational Site | Tampa | Florida | 33616 | — |
| Curevo Investigational Site | Oak Brook | Illinois | 60523 | — |
| Curevo Investigational Site | Lenexa | Kansas | 66219 | — |
| Curevo Investigational Site | Newton | Kansas | 67114 | — |
| Curevo Investigational Site | Lexington | Kentucky | 40509 | — |
| Curevo Investigational Site | Las Vegas | Nevada | 89119 | — |
| Curevo Investigational Site | Edmond | Oklahoma | 73013 | — |
| Curevo Investigational Site | Knoxville | Tennessee | 37909 | — |
| Curevo Investigational Site | Austin | Texas | 78745 | — |
| Curevo Investigational Site | Dallas | Texas | 75251 | — |
| Curevo Investigational Site | Euless | Texas | 76040 | — |
| Curevo Investigational Site | Salt Lake City | Utah | 84107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05304351, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 30, 2025 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05304351 live on ClinicalTrials.gov.